How This Works
Semax is a synthetic analog of the ACTH(4–10) fragment with a C‑terminal Pro‑Gly‑Pro tripeptide extension that enhances metabolic stability[1][5]. Clinical and preclinical literature suggest it modulates brain‑derived neurotrophic factor (BDNF) expression, enhances cholinergic and dopaminergic neurotransmission, and exhibits neuroprotective properties in models of cerebrovascular and cognitive impairment[2][5]. Human studies in Russia have employed Semax for cognitive support in conditions ranging from mild cognitive impairment to acute stroke recovery, typically using intranasal preparation[2][3][6]. delivery offers an alternative route with potentially more sustained systemic absorption[1][4].
References
Neuroscience and Behavioral Physiology (Springer)
— Comparative study of Semax preparation routes (intranasal vs. ) in animal models
Vidal Drug Reference (Russia)
— Official prescribing information for Semax 0.1% intranasal drops; human measurement guidelines and preparation schedules
Journal of Neurology and Psychiatry (Russia)
— Clinical trial of Semax in ischemic stroke research samples (6,000 mcg/day intranasal protocol with cycling)
Peptides.org
— Semax measurement overview, cycling recommendations, and protocol duration guidance
Journal of Higher Nervous Activity (Russia)
— Early human study introducing Semax’s nootropic properties and mechanism of action
Vestnik Oftalmologii (Russian Ophthalmology Journal)
— Human study of Semax in glaucomatous optic neuropathy; 30‑day safety data
Johns Hopkins Arthritis Center
— Clinical guide to handling reference (preparation, angle, site rotation)
CDC
— Vaccine preparation guidelines for measurements (angle, no aspiration)
Pharmaceutics (MDPI)
— Overview of Russian peptide drugs including Semax; formulation stability and storage considerations
Drug Testing and Analysis (Wiley)
— Review of nootropic peptides including Semax; discussion of human intranasal use patterns